Further, in DESTINY-Lung01, a phase II study of 91 patients with previously treated HER2-mutated NSCLC, ORR was 55% [95% CI 44–64], and PFS was 8.2 [95% CI 6.0–11.9] [50] (NCT03505710) (Table 2). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.